Skip to content

5-MeO-DMT: all studies

Page 10 of 110: studies 91 to 100 of 1,095, newest first. Back to the 5-MeO-DMT overview

Research

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

Clinical Pharmacokinetics February 1, 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al. 7 citations

N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT. Clinical studies that administered known amounts of DMT and reported PK data and/or...

DOI: 10.1007/s40262-024-01450-8 (opens in new tab) Full text (opens in new tab) DMT Psychedelics Pharmacology Mental health treatment

Clinical pharmacokinetics of N,N-dimethyltryptamine (DMT): a systematic review and post-hoc analysis

Leiden Repository 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al.

BACKGROUND AND OBJECTIVE\nMETHODS\nRESULTS\nCONCLUSION\nN,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT.\nClinical studies that administered...

DOI: 10.1007/s40262-024-01450-8#citeas (opens in new tab) Pharmacokinetics Bolus digestion Volume of distribution Dosing +2

Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT.

Frontiers in Psychology 2025 Johannes T. Reckweg, Natasha L. Mason, Eef L. Theunissen et al. 2 citations

A three-item Peak Experience Scale (PES) was developed to rapidly evaluate the strength of the psychoactive experience, and to guide the dosing regimen, of the psychedelic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; mebufotenin). This paper aims to compare the PES with a range of established questionnaires designed to evaluate the psychedelic experience. Data were gathered from three separate...

Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.

Molecular Psychiatry 2025 Margareth Nogueira, Daiane C Ferreira Golbert, Richardson Menezes et al. 18 citations

Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are suggested to have plasticity-inducing action. However, a comprehensive mechanism of action is still lacking. Here, we investigated how a single dose of the short-acting 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) acts on gene expression from microdissected...

DOI: 10.1038/s41380-024-02655-w (opens in new tab) Full text (opens in new tab) Psychopharmacology Anxiety research Natural compounds

Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness.

Neuroscience of Consciousness 2025 Christopher Timmermann, James W. Sanders, David Reydellet et al. 19 citations

5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews,...

DOI: 10.1093/nc/niaf007 (opens in new tab) Full text (opens in new tab) Serotonin EEG Neurophenomenology Consciousness-research +3

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.

The International Journal of Neuropsychopharmacology December 28, 2024 Michael J Mueller, Helena Aicher, Dario Dornbierer et al. 10 citations

Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea,...

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

Neuropsychopharmacology December 19, 2024 Livio Erne, Severin B Vogt, Lorenz Müller et al. 14 citations

Abstract N,N -dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a subsequent continuous infusion. However, data on dose-dependent acute effects and pharmacokinetics of continuous DMT infusions are lacking. We...

DOI: 10.1038/s41386-024-02041-8 (opens in new tab) Full text (opens in new tab) Psychedelic medicine DMT Research Controlled substance trials Psychopharmacology +1

Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice.

ACS Chemical Neuroscience December 18, 2024 Grant C. Glatfelter, Allison A Clark, Natalie G. Cavalco et al. 14 citations

5-methoxy-N,N-dimethyltrytpamine (5-MeO-DMT) analogs are used as recreational drugs, but they are also being developed as potential medicines, warranting further investigation into their pharmacology. Here, we investigated the neuropharmacology of 5-MeO-DMT and several of its N-alkyl, N-allyl, and 2-methyl analogs, with three major aims: 1) to determine in vitro receptor profiles for the...

Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.

ACS Medicinal Chemistry Letters November 14, 2024 Robert B. Kargbo 3 citations

Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in treating various mental health disorders. This Patent Highlight evaluates findings from multiple recent patents that explore novel applications of these compounds, including their use in severe psychiatric conditions such as depression, anxiety, and...

DOI: 10.1021/acsmedchemlett.4c00490 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Alternative medicine Depression treatment Therapeutic compounds +1

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.

Frontiers in Psychiatry November 6, 2024 Cristiano Chaves, Rafael G. Dos Santos, Serdar Dursun et al. 11 citations

The "wine of jurema", used in ancient Brazilian shamanic rituals, is rich in N,N-dimethyltryptamine (DMT), a naturally occurring tryptamine like serotonin and melatonin. Widely found in plants and animals, DMT is the main component of some botanical tisanes used for centuries as a channel of communication with the otherworld (1, 2). Despite being classified as a "classical psychedelic” (2-4),...

DOI: 10.3389/fpsyt.2024.1485337 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Pharmacology Therapeutic research